
|Articles|February 1, 2005
Glaucoma agent lowers IOP by dual mechanism
New Orleans—Travoprost 0.004% (Travatan, Alcon Laboratories) lowers IOP by both increasing outflow facility and improving uveoscleral outflow, according to the results of a clinical study designed to investigate the mechanism of action of travoprost.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
AAO 2025: Philip J. Ferrone, MD, highlights safety and efficacy findings of gildeuretinol in Stargardt disease
2
AAO 2025: Glaucoma laser surgery with Joel S. Schuman, MD, FACS
3
News from Orlando: AAO 2025 highlights research across all areas of eyecare
4
AAO 2025: Which lens to consider in patients with pseudoexfoliation
5